Article Details

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies ...

Retrieved on: 2020-12-10 12:11:15

Tags for this article:

Click the tags to see associated articles and topics

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies .... View article details on hiswai:

Excerpt

Ublituximab (TG-1101) is a novel, glycoengineered <b>monoclonal antibody</b> that targets a specific and unique epitope on the CD20 antigen found on ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up